Epigenetic modifications of the estrogen receptor β gene in epithelial ovarian cancer cells

Anticancer Research

Volumn 29, Issue 1, 2009, Pages 139-144

  Yap, O I Wah Stephanie ^a,d   Bhat, Ganapathy ^a   Liu, Liang ^b   Tollefsbol, Trygve O ^c,e  

^a MOREHOUSE SCHOOL OF MEDICINE   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d Southeastern Gynecologic Oncology   (United States)

^e NONE   (United States)

Author keywords

Dna methylation; Epigenetic; Estrogen receptor; Histone deacetylation; Ovarian cancer

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; TRICHOSTATIN A;

ARTICLE; CANCER CELL CULTURE; CPG ISLAND; DEMETHYLATION; DNA METHYLATION; DRUG EFFECT; EPIGENETICS; ERBETA GENE; GENE; GENE SILENCING; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; OVARY CANCER; PRIORITY JOURNAL; PROMOTER REGION;

AZACITIDINE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; ENZYME INHIBITORS; ESTROGEN RECEPTOR BETA; FEMALE; HISTONE ACETYLTRANSFERASES; HUMANS; HYDROXAMIC ACIDS; OVARIAN NEOPLASMS; PROMOTER REGIONS, GENETIC;

EID: 61449106828     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics. CA Cancer J Clin 57: 43-66, 2007.
2. Barnholtz-Sloan JS, Schwartz AG, Qureshi F, Jacques S, Malone J and Munkarah AR: Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. Am J Obstet Gynecol 189: 1120-1127, 2003.
3. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA et al: Phase III of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 21: 3194-3200, 2003.
4. Lacey Jr JV, Mink PJ, Lubin JH, Sherman ME, Troisi R, Hartge P et al: Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 288: 334-341, 2002.
5. Cunat S, Hoffmann P and Pujol P: Estrogens and epithelial ovarian cancer. Gynecol Oncol 94: 25-32, 2004.
6. Perez-Gracia JL and Carrasco EM: Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: systematic review of the literature and implications for future research. Gynecol Oncol 84: 201-209, 2002.
7. Markman M, Iseminger KA, Hatch KD, Creasman WT, Barnes W and Dubeshter B: Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report. Gynecol Oncol 62: 4-6, 1996.
8. Markman M, Webster K, Zanotti K, Rohl J and Belinson J: Use of tamoxifen in asymptomatic patients with recurrent small-volume ovarian cancer. Gynecol Oncol 93: 390-393, 2004.
9. Brandenberger AW, Tee MK and Jaffe RB: Estrogen receptor alpha (ER-α) and beta (ER-β) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-β in neoplastic tissues. J Clin Endocrinol Metab 83: 1025-1028, 1998.
10. Lau K, Mok SC and Ho S: Expression of human estrogen receptor-α and -β, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. Proc Natl Acad Sci, USA 96: 5722-5727, 1999.
11. Li AJ, Baldwin RL and Karlan BY: Estrogen and progesterone receptor subtype expression in normal and malignant ovarian epithelial cell cultures. Am J Obstet Gynecol 189: 22-27, 2003.
12. Pujol P, Rey JM, Nirde P, Roger P, Gastaldi M, Laffarque F, Rochefort H et al: Differential expression of estrogen receptor-alpha and -beta messenger RNA as a potential marker of ovarian carcinogenesis. Cancer Res 58: 5367-5373, 1998.
13. Rutherford T, Brown WD, Sapi E, Aschkenazi S, Munoz A and Mor G: Absence of estrogen receptor-β expression in metastatic ovarian cancer. Obstet Gynecol 96: 417-421, 2000.
14. Bardin A, Hoffmann P, Boulle N, Katsaros D, Vignon F, Pujol P et al: Involvement of estrogen receptor β in ovarian carcinogenesis. Cancer Res 64: 5861-5869, 2004.
15. Yang X, Ferguson AT, Nass SJ, Phillips DL, Butash KA, Wang SM et al: Transcriptional activation of estrogen receptor α in human breast cancer cells by histone deacetylase inhibition. Cancer Res 60: 6890-6894, 2000.
16. Sasaki M, Kaneuchi M, Fujimoto S, Tanaka Y and Dahiya R: Hypermethylation can selectively silence multiple promoters of steroid receptors in cancers. Mol Cell Endocrinol 202: 201-207, 2003.
17. Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE and Baylin SB: Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet 7: 536-540, 1994.
18. Ferguson AT, Lapidus RG, Baylin SB and Davidson NE: Demethylation of the estrogen receptor in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res 55: 2279-2283, 1995.
19. Jang ER, Lim SJ, Lee ES, Jeong G, Kim TY, Bang YU et al: The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor a-negative breast cancer cells to tamoxifen. Oncogene 23: 1724-1736, 2004.
20. Baylin SB, Makos M, Wu J, Yen RC, deBustros A, Vertino PM et al: Abnormal patterns of DNA methylation in human neoplasia: potential consequences for tumor progression. Cancer Cells 3: 383-390, 1991.
21. Balch C, Huang TH, Brown R and Nephew KP: The epigenetics of ovarian cancer drug resistance and resensitization. Am J Obstet Gynecol 191: 1552-1572, 2004.
22. Wei SH, Chen CM, Strathdee G, Harnsomburana J, Shyu CR, Rahmatpanah F et al: Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin Cancer Res 8: 2246-2252, 2002.